Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
NCT06845241
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
68
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed or Refractory Non-Hodgkin Lymphoma
Interventions
DRUG:
ICP-490
Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.